TABLE 1.
Baseline characteristics of HCC patients for the entire cohort
| n = 344 | |||
|---|---|---|---|
| Variable | n | % | |
| Gender | Male | 296 | 86.0% |
| Female | 48 | 14.0% | |
| Age (years) | ≤50 | 141 | 41.0% |
| >50 | 203 | 59.0% | |
| CTC Count | <1 | 123 | 35.8% |
| ≥1 | 221 | 64.2% | |
| Tumor number | Single | 259 | 75.3% |
| Multiple | 85 | 24.7% | |
| Tumor diameter (cm) | ≤5 | 219 | 63.7% |
| >5 | 125 | 36.3% | |
| Tumor capsule | Complete | 206 | 59.9% |
| None | 138 | 40.1% | |
| Vascular invasion | No | 203 | 59.0% |
| Yes | 141 | 41.0% | |
| Edmondson stage | I‐II | 209 | 60.8% |
| III‐IV | 135 | 39.2% | |
| Liver cirrhosis | No | 154 | 44.8% |
| Yes | 190 | 55.2% | |
| HBsAg | Negative | 49 | 14.2% |
| Positive | 295 | 85.8% | |
| AFP (ng/mL) | ≤400 | 240 | 69.8% |
| >400 | 104 | 30.2% | |
| ALT (U/L) | ≤50 | 274 | 79.7% |
| >50 | 70 | 20.3% | |
| GGT (U/L) | ≤60 | 202 | 58.7% |
| >60 | 142 | 41.3% | |
| Child‐Pugh class | A | 339 | 98.5% |
| B | 5 | 1.5% | |
| BCLC stage | 0‐A | 254 | 73.8% |
| B‐C | 90 | 26.2% | |
| CNLC stage | I | 254 | 73.8% |
| II‐III | 90 | 26.2% | |
| TACE | No | 238 | 69.2% |
| Yes | 106 | 30.8% | |
Abbreviations: AFP, alpha‐fetoprotein; ALT, alanine aminotransferase; BCLC, Barcelona Clinic Liver Cancer staging system; CNLC, Liver Cancer Guidelines in China; CTC, circulating tumor cell; GGT, gamma‐glutamyl transpeptidase; HBsAg, Hepatitis B surface antigen; HCC, hepatocellular carcinoma; TACE, transcatheter arterial chemoembolization.